Business
Modular Medical Receives IRB Approval to Deliver Insulin Using Pivot Patch Pump
Study to Deliver Insulin to Internal Testers Wearing Continuous Glucose Monitors SAN DIEGO, CA / ACCESS Newswire / November 17, 2025 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a leader in innovative insulin delivery ...
About this update from Modular Medical, Inc.
[{"type":"text","content":"Study to Deliver Insulin to Internal Testers Wearing Continuous Glucose Monitors","length":80,"tagName":"p"},{"type":"text","content":"SAN DIEGO, CA / ACCESS Newswire / November 17, 2025 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a leader in innovative insulin delivery technology targeting the $3 billion adult "almost-pumpers" diabetes market with user-friendly, affordable patch pumps, today announced Institutional Review Board ("IRB") approval to conduct an in-house study of its next-generation Pivot™ insulin delivery system using insulin on people with diabetes (the "Study"). Pursuant to U.S. Food and Drug Administration ("FDA") regulations, an IRB is a group that has been formally designated to review and monitor biomedical research involving human subjects. The Study will simulate real-world conditions by delivering insulin to adult participants to gather critical data on device function and usability and obtain user feedback.","length":902,"tagName":"p"},{"type":"text","content":"Modular Medical's Pivot tubeless patch pump aims to enhance accessibility for underserved patients with diabetes and drive market penetration and expansion.","length":160,"tagName":"p"},{"type":"text","content":"Key objectives and potential impacts of the Study include:","length":58,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Assess usability and the patient experience","length":43,"tagName":"p"}]},{"val":[{"type":"text","content":"Collect participant feedback to optimize design for everyday diabetes management","length":80,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":123,"olType":false},{"type":"text","content":""This IRB approval marks another important milestone in advancing our tubeless insulin pump technology toward market readiness," said Jeb Besser, CEO of Modular Medical. "We now have approval to gather real-world data delivering insulin to adult test subjects in a controlled environment, as we await FDA feedback on our recent Pivot 510k submission. Once FDA clearance is achieved, we believe our Pivot pump will be well positioned to achieve rapid adoption in the growing wearable diabetes technology sector."The Pivot insulin delivery system is not currently cleared for sale by the ...